What is Driving the Current Oncology Revolution?
Cancer remains the world’s second leading cause of death, but the trajectory of oncology is undergoing its most consequential transformation in decades. Immunotherapy, precision medicine, and artificial intelligence are converging to produce treatment modalities that were unimaginable twenty years ago. The WHO Global Cancer Report 2025 estimates that global cancer incidence will reach 35 million new cases annually by 2050 — a 77% increase on 2022 levels — driven by population ageing, urbanisation, and the persistence of high-risk behavioural factors. The scale of this burden is simultaneously a humanitarian challenge and a structural driver of investment in oncology infrastructure, diagnostics, and therapeutics.
Constancy Researchers observes that the response from the biopharma and medtech sectors has been proportionate to the challenge. According to the IQVIA Global Oncology Trends 2025 Report, global oncology spending reached $237 billion in 2024, and is projected to exceed $370 billion by 2028 — the single largest therapeutic category in pharmaceutical expenditure worldwide. This is not a niche market; it is the defining arena of biopharmaceutical competition.
Immuno-Oncology: The Dominant Therapeutic Paradigm
No scientific development has reshaped oncology more fundamentally over the past decade than immuno-oncology — the harnessing of the immune system to recognise and destroy tumour cells. The approval of checkpoint inhibitors targeting the PD-1/PD-L1 pathway opened a new therapeutic era, with Merck’s pembrolizumab (Keytruda) now approved across more than 40 tumour types and indications. Constancy Researchers notes that Keytruda alone generated $25 billion in global revenue in 2024, the highest of any oncology drug in history.
The next frontier is combination therapy — pairing checkpoint inhibitors with targeted therapies, antibody-drug conjugates (ADCs), or cell therapies to overcome resistance and expand efficacy. The American Society of Clinical Oncology (ASCO) Annual Report 2025 identified combination immunotherapy strategies as the single most active area of clinical investigation, with over 4,000 combination trials globally currently underway. As Constancy Researchers tracks, the firms that succeed in establishing dominant combination platforms will hold structural advantages that persist across multiple product cycles.
ADCs and Targeted Therapies: Precision Redefined
Antibody-drug conjugates represent one of the highest-conviction growth platforms in all of biopharma. By linking a tumour-targeting antibody to a cytotoxic payload, ADCs deliver chemotherapy with unprecedented precision — sparing healthy tissue and dramatically improving the therapeutic index. The EvaluatePharma World Preview 2025 projects the ADC market will grow from $14 billion in 2024 to over $50 billion by 2030, a compound annual growth rate exceeding 20%.
Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan (Enhertu) has become the benchmark product, demonstrating efficacy across HER2-expressing cancers of the breast, lung, and gastric origin. The FDA’s Oncology Center of Excellence 2024 Annual Report confirmed a record 67 oncology approvals in the United States in 2024, the highest single-year total on record, with ADCs and targeted small molecules accounting for the majority. Constancy Researchers identifies this approval cadence as a structural catalyst for sector revenue growth through the remainder of the decade.
Cell and Gene Therapies: The Long-Duration Bet
CAR-T cell therapy has moved from experimental treatment to established standard of care for several haematological malignancies. Products from Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, and Novartis are now embedded in treatment guidelines for multiple myeloma, large B-cell lymphoma, and acute lymphoblastic leukaemia. The Alliance for Regenerative Medicine State of the Industry Briefing 2025 reported global cell and gene therapy investment at $19.8 billion in 2024, with oncology applications representing over 60% of active clinical programmes.
The structural challenge — and the primary competitive battleground — is manufacturing scalability and cost reduction. Current autologous CAR-T therapies carry list prices exceeding $400,000–$500,000 per treatment, limiting access across healthcare systems. Constancy Researchers notes that the shift toward allogeneic (off-the-shelf) CAR-T platforms, pioneered by companies including Allogene Therapeutics and Cellectis, represents both a cost-reduction strategy and a potential paradigm shift in cell therapy accessibility. Successful allogeneic commercialisation would expand the addressable market by an order of magnitude.
Artificial Intelligence: Compressing the Drug Discovery Timeline
Artificial intelligence is restructuring every stage of the oncology drug development pipeline — from target identification and molecular design through clinical trial optimisation and companion diagnostics. The McKinsey Global Institute report on AI in Life Sciences (2025) estimates that AI-enabled approaches could compress the average drug discovery timeline by up to 50% and reduce candidate attrition rates by approximately 30%, with oncology representing the highest-value application domain.
Partnerships between AI-native companies and established pharmaceutical players are accelerating. AstraZeneca’s collaboration with BenevolentAI, Roche’s acquisition of Flatiron Health, and the proliferation of generative AI-based protein design platforms such as Isomorphic Labs — a spin-out from DeepMind — reflect an industry consensus that AI-driven target discovery is now a competitive necessity. Constancy Researchers assesses that the firms building proprietary oncology-specific AI datasets today are constructing durable informational moats that will compound in value as training data requirements grow.
Capital Markets and M&A: Oncology as the Core Biopharma Thesis
The financial markets have aligned unambiguously around oncology as the primary value-creation engine in biopharmaceuticals. According to PitchBook’s 2025 Biopharma Deal Tracker, oncology-focused companies accounted for over 55% of all biopharma venture investment in 2024, with a significant concentration in clinical-stage companies developing next-generation ADCs, bispecific antibodies, and cell therapies. Total biopharma M&A activity reached $220 billion in 2024, with oncology assets at the centre of the five largest transactions.
Large-cap pharmaceutical companies — facing patent cliffs on legacy blockbusters through 2028–2032 — are deploying capital at scale to replenish pipelines through oncology acquisition. Pfizer’s $43 billion acquisition of Seagen, AbbVie’s $10.1 billion purchase of ImmunoGen, and Bristol-Myers Squibb’s $14 billion acquisition of RayzeBio collectively signal that oncology M&A is entering a structurally elevated cycle. Constancy Researchers identifies this dynamic as creating significant opportunity for differentiated mid-cap oncology platforms that have established clinical proof of concept.
Regional Landscape: Where the Oncology Buildout is Most Intense
North America remains the global centre of oncology innovation, accounting for approximately 60% of active oncology clinical trials and over 70% of oncology venture investment. The Inflation Reduction Act’s drug pricing provisions have introduced uncertainty around revenue trajectories for certain oncology drugs in the US market, but Constancy Researchers notes that the structural pipeline density and capital availability in North America have no near-term parallel.
Europe is executing a significant expansion of oncology research infrastructure under Horizon Europe, with the EU Mission on Cancer committing to reduce premature cancer mortality by 10% by 2030 and achieving a 3 million life-year improvement target. The European Medicines Agency is under pressure to accelerate oncology approval timelines to match the FDA’s pace, representing a structural regulatory tailwind for companies pursuing global launches.
Asia-Pacific — and China in particular — is both a growing commercial market and an increasingly formidable innovation hub. Chinese biotechs have progressed from licensing Western assets to generating novel, globally competitive molecules. The China National Medical Products Administration (NMPA) approved over 50 oncology drugs in 2024, and Chinese companies are now actively licensing oncology assets to global pharma, reversing the historical direction of capital and knowledge flow. Constancy Researchers identifies this as one of the decade’s most strategically significant shifts in pharmaceutical power dynamics.
Pipeline & Clinical Trial Spotlight: Programmes Defining the Next Decade
The breadth and ambition of the current oncology clinical pipeline is without historical precedent. The ClinicalTrials.gov database lists over 12,000 active oncology trials globally as of early 2026, spanning every major tumour type and covering modalities from small molecules and monoclonal antibodies through to mRNA therapeutics, radioligand therapies, and next-generation cell engineering platforms. Constancy Researchers highlights four programme clusters that are attracting the highest levels of scientific and commercial attention.
Radioligand therapies (RLTs) represent one of the fastest-emerging categories in solid tumour oncology. Novartis’s lutetium-177-PSMA-617 (Pluvicto) established proof of concept in metastatic castration-resistant prostate cancer, and the FDA’s approval of Pluvicto in 2022 catalysed a wave of follow-on investment. Pipeline programmes are now targeting breast, lung, neuroendocrine, and colorectal cancers using next-generation radioisotopes including actinium-225, which delivers higher-energy alpha particle radiation with a shorter tissue range, potentially improving efficacy and tolerability simultaneously.
Bispecific antibodies — engineered to bind two distinct targets simultaneously — have moved rapidly from scientific concept to commercial reality. Johnson & Johnson’s teclistamab and talquetamab, both approved for relapsed/refractory multiple myeloma, have demonstrated deep and durable responses in heavily pre-treated patients. The American Association for Cancer Research (AACR) Annual Meeting 2025 featured over 200 bispecific antibody data presentations, with emerging programmes targeting lung, ovarian, and pancreatic cancers — indications where current standard-of-care outcomes remain deeply inadequate.
KRAS-targeted therapies mark one of oncology’s most celebrated scientific breakthroughs. For three decades, KRAS — mutated in approximately 25% of all human cancers — was considered undruggable. Amgen’s sotorasib and Mirati Therapeutics’ adagrasib established that KRAS G12C can be selectively inhibited, and the pipeline of next-generation pan-KRAS inhibitors now in clinical development — including programmes from Revolution Medicines, Relay Therapeutics, and Eli Lilly — aims to address the broader KRAS mutation landscape across pancreatic, colorectal, and non-small cell lung cancers, representing a potential commercial opportunity exceeding $20 billion annually.
What Does the Oncology Inflection Point Mean for the Decade Ahead?
As assessed by Constancy Researchers, the oncology sector is operating at the intersection of five structural tailwinds: an accelerating scientific frontier across immunotherapy, ADCs, and cell and gene therapy; record capital deployment from both strategic and financial investors; AI-driven compression of development timelines; a global regulatory environment adapting to the pace of innovation; and an unmet need of historic scale that guarantees demand for effective therapies regardless of macroeconomic conditions. Companies, payers, and health systems that treat oncology strategy as a core organisational capability — not a reactive response to individual drug launches — will be structurally better positioned to generate and capture value through this transformation. Constancy Researchers continues to monitor these developments across all major geographies, modalities, and commercial dimensions.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
